The US FDA has rebuffed, for now, Teva Pharmaceutical Industries' bid to block approval of generic competition to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).
In denying a citizen's petition submitted by Teva, the agency said it would be inappropriate to set forth specific requirements...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?